Cyclacel Pharmaceuticals, Inc. Announces Sapacitabine Poster Presentation at Upcoming American Society of Hematology Meeting
BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today updated Phase I clinical trial results of sapacitabine for the treatment of advanced leukemias or myelodysplastic syndromes will be presented at the 2007 American Society of Hematology (ASH) 49th Annual Meeting in Atlanta, GA, on Saturday, December 8, 2007.